scholarly journals TA-2005, a Novel, Long-Acting, and Selective .BETA.2-Adrenoceptor Agonist: Characterization of Its in Vivo Bronchodilating Action in Guinea Pigs and Cats in Comparison with Other .BETA.2-Agonists.

1994 ◽  
Vol 17 (8) ◽  
pp. 1047-1052 ◽  
Author(s):  
Hideo KIKKAWA ◽  
Kenkichi KANNO ◽  
Katsuo IKEZAWA
Keyword(s):  
Guinea Pigs ◽  
Adrenoceptor Agonist ◽  
Beta 2 ◽  
Long Acting

scholarly journals Salmeterol, a novel, long-acting β2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo

1991 ◽  
Vol 104 (3) ◽  
pp. 665-671 ◽  
Author(s):  
D.I. Ball ◽  
R.T. Brittain ◽  
R.A. Coleman ◽  
L.H. Denyer ◽  
D. Jack ◽  
...  
Keyword(s):  
Pharmacological Activity ◽  
Adrenoceptor Agonist ◽  
Long Acting

In Vivo Neurochemical Characterization of Developing Guinea Pigs and the Effect of Chronic Fetal Hypoxia

2016 ◽  
Vol 41 (7) ◽  
pp. 1831-1843 ◽  
Author(s):  
Wen-Tung Wang ◽  
Phil Lee ◽  
Yafeng Dong ◽  
Hung-Wen Yeh ◽  
Jieun Kim ◽  
...  
Keyword(s):  
Guinea Pigs ◽  
Fetal Hypoxia

Anabolic effects of the beta 2-adrenoceptor agonist salmeterol are dependent on route of administration

1994 ◽  
Vol 267 (3) ◽  
pp. E475-E484 ◽  
Author(s):  
N. G. Moore ◽  
G. G. Pegg ◽  
M. N. Sillence
Keyword(s):  
Soleus Muscle ◽  
Body Weight Gain ◽  
Route Of Administration ◽  
Duration Of Action ◽  
Routes Of Administration ◽  
Adrenoceptor Agonists ◽  
Slow Twitch ◽  
Beta 2 ◽  
Long Acting

It is reported that a long duration of action is required for beta 2-adrenoceptor agonists to evoke an anabolic response. In the present study, we compare the potency of clenbuterol with that of the new long-acting compound salmeterol, when given at equimolar doses to female Wistar rats by different routes of administration. Given orally for 10 days, salmeterol had no effect on growth at a dose of 120 micrograms/day, whereas at 2.4 mg/day the drug caused significant increases in body and carcass weight and in the mass of the mixed-fiber gastrocnemius/plantaris and tibialis anterior muscles, but there were no increases in the slow-twitch soleus muscles. A similar growth response was seen when clenbuterol was given orally at a dose of only 97 micrograms/day, with an additional response seen in soleus muscle at 1.9 mg/day. Thus clenbuterol was more potent than salmeterol when given by this route of administration. When the drugs were infused by osmotic minipump, both salmeterol (130 micrograms/day) and clenbuterol (100 micrograms/day) caused increases in body weight gain and in the weights of the mixed-fiber muscles, with the most dramatic effect of infusion being to greatly increase the anabolic effect of salmeterol in soleus muscle. A single intraperitoneal injection of salmeterol (53 micrograms) or clenbuterol (40 micrograms) caused a similar rapid increase in the concentration of adenosine 3',5'-cyclic monophosphate in gastrocnemius muscle. These results indicate that the potency of salmeterol in vivo is dependent on its route of administration and that slow-twitch muscles are less sensitive than mixed-fiber muscles to the anabolic effects of beta 2-adrenoceptor agonists.

Characterization of in vitro and in vivo platelet responses to thrombin and thrombin receptor-activating peptides in guinea pigs

1997 ◽  
Vol 321 (1) ◽  
pp. 129-135 ◽  
Author(s):  
Peter J.S. Chiu ◽  
Glen G. Tetzloff ◽  
Carolyn Foster ◽  
Madhu Chintala ◽  
Edmund J. Sybertz
Keyword(s):  
Guinea Pigs ◽  
Thrombin Receptor

scholarly journals In Vitro and in Vivo Characterization of MOD-4023, a Long-Acting Carboxy-Terminal Peptide (CTP)-Modified Human Growth Hormone

2016 ◽  
Vol 13 (2) ◽  
pp. 631-639 ◽  
Author(s):  
Oren Hershkovitz ◽  
Ahuva Bar-Ilan ◽  
Rachel Guy ◽  
Yana Felikman ◽  
Laura Moschcovich ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Human Growth ◽  
Long Acting ◽  
Carboxy Terminal ◽  
In Vivo Characterization

scholarly journals Pharmacological and clinical profile of indacaterol maleate (Onbrez^|^reg;), an inhaled long-acting ^|^beta;2-adrenoceptor agonist

2012 ◽  
Vol 140 (1) ◽  
pp. 36-43
Author(s):  
Kazuhiko Suzuki ◽  
Masahiko Uchiyama ◽  
Soichiro Matsushima ◽  
Mika Yoshiki ◽  
Tetsuji Kitawaki
Keyword(s):  
Clinical Profile ◽  
Adrenoceptor Agonist ◽  
Beta 2 ◽  
Long Acting
Sign in / Sign up

Export Citation Format

Share Document